Tag Archives: Patents

The United States Patent and Trademark Office.  By Paul J. Richards (AFP/Getty Images)

Tribal Lawyer Shops Patent-Shielding Idea to State Universities

Tribal Lawyer Shops Patent-Shielding Idea to State Universities

By Susan Decker, Bloomberg News Despite a federal judge’s skepticism of a drugmaker’s attempt to shield patents by selling them to an Indian tribe, the tribe’s lawyer is inviting other organizations to take advantage of the idea. He’s in talks with some state universities, historically black colleges and other Indian tribes with funding woes that

Photo by Michael Nagle / Bloomberg

Lilly Wins U.S. Patent Challenges to Its Alimta Cancer Drug

By Susan Decker and Tatiana Darie, Bloomberg News Eli Lilly & Co. won a challenge to the validity of a patent that keeps generic versions of its $2 billion lung cancer drug Alimta off the U.S. market until 2022. The Patent Trial and Appeal Board rejected arguments by companies including Teva Pharmaceutical Industries Ltd., Novartis

Photo by Andrew Harrer (Bloomberg)

Court Revisits Patent Office Lawyer Fees When Rejected Filers Sue

By Peter Leung, Bloomberg BNA The nation’s patent appeals court reopened a dispute about whether patent filers who contest rejections in district court must pay the Patent and Trademark Office’s lawyer fees. A majority of a three-judge panel in June said that appealing patent filers must pay the lawyer fees, because a statute requires the

Photographer: Susana Gonzalez/Bloomberg

Cost of Patent Infringement Litigation Falling Sharply

By Malathi Nayak, Bloomberg BNA Patent litigation costs declined drastically from 2015 to 2017, as litigants controlled expenses and increasingly skipped courtrooms to challenge a patent’s validity at the Patent and Trademark Office, IP attorneys told Bloomberg BNA. The median overall cost for a patent infringement case with $1 million to $10 million at stake

Anti-clot drug Lovenox is arranged for an illustration at C O Bigelow Pharmacy in New York, New York Tuesday, November 6, 2007. Sanofi-Aventis SA, the maker of the anti-clot drug Lovenox, rose the most in 16 months in Paris trading after U.S. regulators rejected a rival copy from Momenta Pharmaceuticals Inc. and Novartis AG. Photographer: JB Reed/ Bloomberg News

Momenta, Novartis Lose U.S. Patent Trial on Generic Lovenox 

By Janelle Lawrence and Susan Decker, Bloomberg News Momenta Pharmaceuticals Inc. lost a patent- infringement trial against Amphastar Pharmaceuticals Inc. over a process to make generic versions of the blood-thinner Lovenox. Momenta pledged to appeal. A Momenta patent is invalid, a federal jury in Boston decided Friday. Momenta dropped as much as 3 percent on

The US Supreme Court. (Photo by Olivier Douliery-Pool/Getty Images)

U.S. Supreme Court Curbs Patent-Holder Power to Block Resale

By Greg Stohr and Susan Decker, Bloomberg News The U.S. Supreme Court said companies give up their patent rights when they sell an item, in a ruling that puts new limits on businesses’ ability to prevent their products from being resold at a discount. The ruling is a defeat for Lexmark International Inc., which was

Photographer: Andrew Harrer/Bloomberg

U.S. Supreme Court Puts New Curbs on Locations of Patent Suits

By Greg Stohr and Susan Decker, Bloomberg News The U.S. Supreme Court put sharp new limits on where patent-infringement lawsuits can be filed, undercutting patent owners’ ability to channel cases to favorable courts. The justices on Monday unanimously ruled in favor of TC Heartland LLC, an Indiana-based maker of water flavorings that said a Kraft

Kyle Bass, chief investment officer of Hayman Capital Management LP, speaks during a Bloomberg Television interview in New York, U.S., on Wednesday, Jan. 25, 2017. Photographer: Kholood Eid/Bloomberg

How Patent Trolls Sparked a Failed Assault on High Drug Prices

By Paul Barrett, Bloomberg Businessweek  Hedge fund manager Kyle Bass appears to be wrapping up a generally unsuccessful patent-law assault on drug manufacturers. “In the end, lobbying and special interests pay,” Bass told Bloomberg in a defeatist-sounding email. “Medicare and U.S. consumers pay the ultimate price for the evergreening of bad patents by the pharma

Photographer: Andrew Harrer/Bloomberg

Supreme Court Weighs Possible Curb on Patent Suit Locations

By Susan Decker, Bloomberg News The U.S. Supreme Court grappled over whether to upend a quarter-century of practice and limit where patent- infringement lawsuits can be filed. The justices Monday heard arguments in a case involving water flavoring containers that could end the reign of the Eastern District of Texas, which handles more than a

Top